A Modular Phase I/II Open-label Dose Escalation and Dose Expansion Study to Evaluate the Safety, Pharmacokinetics, Pharmacodynamics, and Efficacy of AZD9793, a T Cell-engaging Antibody Targeting Glypican-3 (GPC3) in Adult Participants With Advanced or Metastatic Solid Tumours (RHEA-1)
Latest Information Update: 03 Feb 2025
Price :
$35 *
At a glance
- Drugs AZD 9793 (Primary) ; AZD 9793 (Primary)
- Indications Advanced breast cancer; Liver cancer
- Focus Adverse reactions; First in man; Therapeutic Use
- Acronyms RHEA-1
- Sponsors AstraZeneca
- 03 Feb 2025 New trial record